In the present study, we conducted a comprehensive assessment to examine the toxicity spectrum of CDK4/6 inhibitors in patients with breast cancer by summarizing evidence from RCTs and performing pharmacovigilance analysis with the data obtained from the Food and Drug Administration Adverse Event Reporting System (FAERS) database (14). This evidence concerns the gene CDK4 and breast cancer.